Company attributes
Venture Capital Firm attributes
Other attributes
Vida Ventures was co-founded by Arie Belldegrun, Fred Cohen, Stefan Vitorovic, Joshua Kazam, Arjun Goyal and Len Potter. Vida Ventures is headquartered in Boston, Massachusetts.
In August 2017, it was reported that Vida Ventures has participated in a $83.5 million Series B financing round for Homology Medicines.
In December 2017, it was announced that Vida Ventures participated in a $62 million Series B financing round for Pionyr Therapeutics.
In March 2018, Homology Medicines, one of the companies Vida Ventures has invested in, began trading on the Nasdaq Global Select Market under the ticker "FIXX". Homology Medicines has raised $165 million in its initial public offering.
In April 2018, it was announced that Vida Ventures participated in a $300 million Series A financing round for Allogene Therapeutics.
In May 2018, it was announced that Vida Ventures participated in a $18 million seed financing round for Kronos Bio.
In July 2018, it was announced that Vida Ventures participated in a $85.4 Series E financing round for Sutro Biopharma.
